In the trials, Trixeo demonstrated statistically significant improvements in lung function compared with combined ICS/LABA comparators
Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage
The results could support Roche’s push to move Lunsumio into earlier lines of treatment
SYNT-101 was designed to produce a specific multi-hormone signature, one that mimics the metabolic response of bariatric surgery but via a once-daily oral tablet
The drug also achieved statistically significant and clinically meaningful improvements across all eight ranked secondary endpoints
The SERENA-4 trial did not meet its primary endpoint of progression-free survival (PFS) in patients with estrogen receptor (ER)-positive
The reduction was particularly notable across eosinophil thresholds
The acquisition brings MLM’s laboratory network and scientific service capabilities into Labcorp’s global infrastructure, expanding the company’s wholly owned laboratory footprint
The findings are particularly significant because the trial population had a high burden of severe obesity
The company said RZ-520 has been designed to maintain drug exposure within the lungs while limiting systemic distribution
The pivotal cardiovascular outcomes trial did not meet its primary endpoint
The company expects to report interim data from MASH patients in 2027
Suven expects the last patient last visit (LPLV) by the end of December 2026
Both were dual primary endpoints of the trial, and the differences were statistically significant, AbbVie said
The study met its primary endpoint
The findings from the SANOVO trial in China strengthen the case for Tagrisso as a backbone treatment for EGFR-mutated non-small cell lung cancer
GSK plans to begin a Phase III efficacy trial in September 2026
The results point to potential benefits beyond relapse control
Subscribe To Our Newsletter & Stay Updated
